- Home
- GILD vs PFE Comparison
GILD vs PFE Comparison
Compare GILD & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | PFE |
|---|---|---|
| Founded | 1987 | 1849 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.6B | 147.6B |
| IPO Year | 2003 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GILD | PFE |
|---|---|---|
| Price | $129.55 | $25.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 14 |
| Target Price | ★ $148.39 | $29.29 |
| AVG Volume (30 Days) | 5.5M | ★ 24.7M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | 2.55% | ★ 6.55% |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | ★ 1.61 | 0.47 |
| Revenue | $24,689,000,000.00 | ★ $62,579,000,000.00 |
| Revenue This Year | $4.68 | N/A |
| Revenue Next Year | $6.04 | N/A |
| P/E Ratio | $80.23 | ★ $54.68 |
| Revenue Growth | ★ 9.98 | N/A |
| 52 Week Low | $107.19 | $23.11 |
| 52 Week High | $157.29 | $28.75 |
Technical Indicators
Market Signals| Indicator | GILD | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 49.32 |
| Support Level | $128.33 | $25.02 |
| Resistance Level | $137.35 | $25.99 |
| Average True Range (ATR) | 3.01 | 0.40 |
| MACD | -0.18 | 0.04 |
| Stochastic Oscillator | 27.44 | 59.11 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.